Replies to post #176630 on Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

Haven't heard or seen a pill form, but it looks to be "doable"

" Gastro retentive drug delivery systems provide dosage forms with longer residence time in the stomach and sustained-release behavior, which can improve bioavailability as well as acting locally on the stomach. Increasing gastric residence time can be achieved either by floating systems that cause buoyancy above gastric fluid, high-density systems that sink to the bottom of the stomach, bioadhesive systems that adhere to mucosal surfaces, or by expandable systems that have limited emptying through the stomach pylorus due to swelling or unfolding to a larger size.


https://www.dovepress.com/design-and-evaluation-of-effervescent-floating-tablets-based-on-hydrox-peer-reviewed-fulltext-article-DDDT




Ran across something interesting while investigating....

Perhaps this could further improve the efficacy of B-OM. I believe it was a Brilacidin (PMX-30063) formulation for oral applications...



Activity of Potent and Selective Host Defense Peptide Mimetics in Mouse Models of Oral Candidiasis

"In order to examine the potential of these compounds as a treatment for oral candidiasis, an optimal delivery system was developed. A hydroxyethylcellulose gel (Natrosol) was selected due to its neutral charge and its current use in many oral applications. Compounds 2, 4, and 5 were dissolved in Natrosol and overlaid with a suspension of C. albicans GDH2346. The results shown in Fig. 3 indicate a rapid killing of Candida in the medium after exposure to the gel. A sampling of the medium applied to the gel indicated a rapid elution of the compounds into the medium (data not shown). This suggests that the observed killing is due to the interaction of the compound with the Candida in the liquid medium, rather than to a direct interaction with the gel. These results indicate that the Natrosol hydrogel represents an efficient method to deliver the antifungal compounds into the saliva for substantive treatment."

https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f80229de4bb7e7c4551dd/1480556579601/Antimicrob.-Agents-Chemother.-2014-Ryan-3820-7.pdf

[biodoc]

Yes, Leo alluded to oral Brilacidin forumulations for treatment of inflammatory bowel disease.

From Dr. Bertolino on 03/16:

“We’re getting exactly what we need from a proof-of-concept study—clear and strong signals both as to the safety and the efficacy of Brilacidin in treating IBD. These results will help guide the continued development of Brilacidin, including planned foam and oral formulations, for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn’s Disease.”

From Leo on 03/21:

“With planned newer formulations, foam and oral, we believe Brilacidin could one day be extended into treating a number of chronic IBD indications.

"